Michelle Allen
Women's Health · Hannibal, MONPI 1902907561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 24.7% of the total.
Across 77 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$330
- Astellas Pharma US Inc$235
- AbbVie$127
- GSK$97
- Sumitomo Pharma America, Inc.$92
- Novo Nordisk$73
- plus $385 from 15 others
What the payments were for
- Food & beverage$1,32799%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $330 |
| Astellas Pharma US Inc | 10 | $235 |
| AbbVie | 7 | $127 |
| GSK | 6 | $97 |
| Sumitomo Pharma America, Inc. | 6 | $92 |
| Novo Nordisk | 5 | $73 |
| Mayne Pharma Commercial LLC | 3 | $65 |
| Novartis | 4 | $64 |
| Boston Scientific | 1 | $39 |
| Johnson & Johnson | 2 | $34 |
| Vertex | 1 | $20 |
| Bayer | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Urovant Sciences Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Exeltis, USA Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $4 |
How this compares
$1,339 in reported general payments places this provider in the 75th percentile of 208 women's health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 54 | $34,100 |
| GemtesaVibegron | 29 | $15,000 |
| Estradiol | 94 | $4,990 |
| Ibandronate Sodium | 64 | $2,274 |
| Alendronate Sodium | 251 | $1,206 |
| ValacyclovirValacyclovir Hcl | 19 | $993 |
| Medroxyprogesterone Acetate | 58 | $628 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $569 |
| Metronidazole | 23 | $524 |
| Nystatin | 54 | $518 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 39 | $475 |
| Clobetasol Propionate | 17 | $431 |
| Acyclovir | 37 | $328 |
| Oxybutynin Chloride | 17 | $264 |
| Triamcinolone Acetonide | 66 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $235 | $34,10054 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $92 | $15,00029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 208 women's health providers in Missouri.
Other women's health in Hannibal
- Kendell FarrHannibal$2K
- Kathryn SimoneBlue Springs$192K
- Nealya Bell-SilvaSaint Louis$107K
- Susan HoffstetterSaint Louis$39K
- Karla WilmotIndependence$22K
- Janice EislebenSaint Louis$16K
- Susan Mitchell-DerenskiSaint Louis$14K
- Amanda SchillySaint Louis$8K
- Jeanette ShanholtzerLees Summit$7K
- Kris ScalfSaint Louis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.